61 Tiotropium Respimat in cystic fibrosis: Efficacy and safety results of phase III randomized placebo-controlled trial

F. Ratjen1, P. Koker2, D. Geller3, B. Langellier-Cocteaux4, F. Le Maulf4, S. Kattenbeck5, P. Moroni-Zentgraf6, J.S. Elborn7. 1The Hospital of Sick Children, Toronto, Canada; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States; 3Florida State University College of Medicine, Orlando, United States; 4Boehringer Ingelheim France SAS, Reims, France; 5Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; 6Boehringer Ingelheim GmbH, Ingelheim, Germany; 7Queen’s University Belfast, Centre for Infection and Immunity, Belfast, N Ireland, United Kingdom